GO
Loading...

Medicine

More

  • Top doctor dies from Ebola after treating dozens Tuesday, 29 Jul 2014 | 9:18 AM ET

    Two American health workers are currently hospitalized with Ebola in neighboring Liberia. The Ebola outbreak is the largest in history with deaths blamed on the disease not only in Sierra Leone and Liberia, but also Guinea and Nigeria.

  • UPDATE 1-Pfizer beats forecasts as oncology drugs grow Tuesday, 29 Jul 2014 | 7:51 AM ET

    July 29- Pfizer Inc, which in May officially abandoned its bid to buy British rival AstraZeneca Plc, reported higher-than-expected second-quarter revenue, helped by growing demand for its cancer medicines.

  • Pfizer beats forecasts as oncology drugs grow Tuesday, 29 Jul 2014 | 7:28 AM ET

    July 29- Pfizer Inc, which in May officially abandoned its bid to buy British rival AstraZeneca Plc, reported higher-than-expected second-quarter earnings, helped by growing sales of its cancer medicines.

  • $1,000 Sovaldi now hepatitis treatment of choice Tuesday, 29 Jul 2014 | 1:57 AM ET

    WASHINGTON— A $1,000- per-pill drug that insurers are reluctant to pay for has quickly become the treatment of choice for a liver-wasting viral disease that affects more than 3 million Americans. In less than six months, prescriptions for Sovaldi have eclipsed all other hepatitis C pills combined, according to new data from IMS Health.

  • Americans fighting Ebola contract deadly virus Monday, 28 Jul 2014 | 8:10 AM ET
    Staff of the Christian charity Samaritan's Purse putting on protective gear in the ELWA hospital in the Liberian capital Monrovia, July 24, 2014.

    Americans Dr. Kent Brantly and aid worker Nancy Writebol contracted Ebola while working to fight the disease in Liberia. NBC News reports.

  • Virus drugmaker fights pediatricians' new advice Monday, 28 Jul 2014 | 12:01 AM ET

    CHICAGO— A costly drug given mostly to premature babies is at the center of a clash between the manufacturer and the nation's leading pediatrician's group, which recommends scaling back use of the medicine.

  • The push back on Sovaldi     Friday, 25 Jul 2014 | 2:52 PM ET

    Insurance companies are hurting from the high cost of hepatitis C drug Sovaldi. Arthur Caplan, NYU Langone Medical Center, and CNBC's Bertha Coombs, share their opinions.

  • *Whereabouts of dozens of victims in Sierra Leone unknown. FREETOWN, July 25- Sierra Leone officials appealed for help on Friday to trace the first known resident in the capital with Ebola whose family forcibly removed her from a Freetown hospital after testing positive for the deadly disease.

  • July 25- AbbVie Inc, which last week announced plans to buy Dublin- based drugmaker Shire Plc for $55 billion, reported stronger-than-expected quarterly results on surging sales of its Humira treatment for rheumatoid arthritis. Excluding special items, AbbVie earned 82 cents per share.

  • *Novo expects to launch in first EU markets in H1 2015. *Shares in Novo rise 1.6 percent. Prospects for degludec- already on sale separately in Europe under the brand name Tresiba- and the new combination with Victoza are critical for Novo, which is the world's biggest insulin maker.

  • Europe backs new leukemia drugs from J&J and Gilead Friday, 25 Jul 2014 | 7:20 AM ET

    LONDON, July 25- Two new leukemia drugs from Johnson& Johnson and Gilead Sciences have been recommended for approval by European regulators, paving the way for formal approval in a couple of months. The European Medicines Agency said on Friday its experts had issued positive opinions for J&J's ibrutinib, developed with Pharmacyclics, and Gilead's idelalisib.

  • LONDON, July 25- A Novo Nordisk drug combining its long-acting insulin degludec with its type 2 diabetes treatment Victoza has been recommended for approval in Europe, in an important boost for the Danish company.

  • July 24- A pivotal trial of Keryx Biopharmaceuticals Inc's experimental drug Zerenex showed that it improved levels of serum phosphorus and iron in patients on kidney dialysis, according to results published on Thursday. The trial involved 441 patients, according to the Journal of the American Society of Nephrology, which published the results.

  • July 24- Bristol-Myers Squibb Co reported better-than-expected quarterly results, helped by cost controls and strong sales of its Eliquis blood clot preventer and Yervoy treatment for melanoma. Sales of Eliquis, which Bristol-Myers co-markets with Pfizer Inc, rose to $171 million.

  • Deadly 'superbug' is spreading in US hospitals Thursday, 24 Jul 2014 | 2:03 PM ET

    CRE, one of the worst of the superbugs, is spreading in some hospitals, and there's worry that cases are under-reported.

  • More US girls now getting cervical cancer vaccine Thursday, 24 Jul 2014 | 1:08 PM ET

    NEW YORK— More teen girls are getting a controversial cervical cancer vaccine but the increase isn't much of a bump, the government reported Thursday. Last year's rise follows a couple of years when the girls' HPV vaccination rate was flat and health officials worried that it wouldn't budge. Anne Schuchat of the Centers for Disease Control and Prevention.

  • *Man collapsed at Lagos international airport. LAGOS, July 24- A Liberian man in his 40 s is being tested for the deadly Ebola virus in Nigeria's commercial capital of Lagos, a mega-city of 21 million people, the Lagos State Health Ministry said on Thursday.

  • Man tested for Ebola in Africa's 'megacity' Lagos Thursday, 24 Jul 2014 | 11:57 AM ET

    A Liberian man is being tested for the deadly Ebola virus in Nigeria's commercial capital of Lagos, a megacity of 21 million people.

  • LAGOS, July 24- A Liberian man in his 40 s is being tested for the deadly Ebola virus in Nigeria's commercial capital of Lagos, a megacity of 21 million people, the Lagos State Health Ministry said on Thursday.

  • GSK asks European regulator to OK malaria shot Thursday, 24 Jul 2014 | 6:50 AM ET

    LONDON— Pharma giant GSK said Thursday it is submitting its malaria vaccine for regulatory approval to the European Medicines Agency. In a statement on Thursday, GSK said its vaccine is aimed only for use against the malaria parasite most prevalent in Africa.